美女免费一级视频在线观看

    • <form id=BiMYPaeIF><nobr id=BiMYPaeIF></nobr></form>
      <address id=BiMYPaeIF><nobr id=BiMYPaeIF><nobr id=BiMYPaeIF></nobr></nobr></address>

      Gold
      




      Novo Nordisk and Toolhouse 
      Sogroya “Imagine the Possibilities” HCP Product Launch 
      




      For people living with growth hormone deficiency (GHD) — a rare condition affecting about one in 10,000 people — a daily injection has been a way of life. In 2021, a long-acting product entered the market, which meant patients could have weekly rather than daily shots.
      




      Sogroya was second to market among these new treatments, which meant it needed to find different ways to introduce itself to healthcare professionals and offer guidance and support as they navigated the rapidly changing treatment landscape.
      




      Part of that was a relatively easy sell: What kid wouldn’t prefer a weekly shot to a daily one? However, busy providers struggle to grasp the new treatment’s clinical benefits compared to the sea of existing once-daily treatments with a long-standing history in the market. And it needed to spell out the difference between Sogroya and its competitors.
      




      In short, endocrinologists and pediatric endocrinologists said they needed more data to believe in the safety and efficacy of Sogroya, and they also worried about access challenges.
      




      This site answers all those needs with a smooth, elegant user experience and simplified clinical data, presented in the most valuable ways. It clearly and visually illustrates the critical differences among competitive products. Easy navigation prioritizes well-articulated data. The site offers a robust library of resources, extensive product support content, financial and formulary information and patient education materials.
      




      Even though GHD is a rare disease, SogroyaPro.com has logged 36,000 visits since  launching in June 2023, with resources being downloaded more than 3,400 times. And more than 80% of site visitors to the Sogroya Pen page interact with the Pen Comparison Tool, suggesting that it is a helpful resource when comparing injection devices.
      




      




      Silver
      




      Corcept Therapeutics and Eversana Intouch  
      In the Clutches of Hypercortisolism
      




      Hypercortisolism is a rare disease that causes the body to overproduce cortisol, but because  its symptoms resemble type 2 diabetes, it often goes undiagnosed. With the insight that few healthcare professionals screen their diabetes patients for the condition, this site gets HCPs’ attention with the HC Creature. This devious enemy catches hold of glucose with its  tentacled arms and won’t let go. Grabby? Yes: Korlym achieved a record number of new prescribers and patients on treatment in Q1, boosting revenue by 39%.
      




      Click here to view 2024 MM+M Award Winners.